LMNB1 and ovarian carcinoma: Treatment with CMP and FSK—potentially involving alterations in LAT1 and lamin B1 (Fig. 5A–C; See Supplementary Figs. S6 and S7)—in combination with olaparib, led to greater reductions in survival across all ovarian cancer cells tested at the lowest concentrations of olaparib (Fig. 6).